Expert Review of Anticancer Therapy

Article	Citations
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence	84
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma	72
Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events	51
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma	44
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?	44
Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma	41
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects	35
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review	32
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence	32
Current status and novel insights into the role of metastasectomy in the era of immunotherapy	28
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review	28
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis	25
Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas	24
Importance of radiation-related cognitive decline in older adults who receive cranial radiation	21
Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes	21
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer	19
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan	19
Prognostic factors of undifferentiated embryonal sarcoma of the liver in children: a SEER-based study	18
Prognostic and clinicopathological value of myeloid-derived suppressor cells in lung cancer: a comprehensive systematic review and meta-analysis	17
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer	17
Progress in histology specific treatments in soft tissue sarcoma	17
Current management of familial adenomatous polyposis	16
An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma	15
Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country	15
Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms	15

Determining factors of neuroplasticity in patients with brain tumors: impact of connectome and artificial intelligence. A narrative review	14
Early detection of hepatocellular carcinoma: roadmap for improvement	13
Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population	13
Supportive care in pediatric acute myeloid leukemia:Expert-based recommendations of the NOPHO-DB-SHIP consortium	13
The importance of autophagy in multiple myeloma	13
EGFR-TKI plus chemotherapy versus TKI monotherapy in advanced EGFR-mutant NSCLC with high PD-L1 expression: a real-world retrospective study	13
Prostate cancer prediction through a hybrid deep learning method applied to histopathological image	13
Elacestrant in metastatic breast cancer: current advancements and future perspectives	13
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer	13
NRF2/KEAP1 signaling inhibitors in gynecologic cancers	13
Deciding individual treatment for primary retroperitoneal sarcoma	12
Current status of robotic surgery for hepato-pancreato-biliary malignancies	12
The long and winding road of faecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy	12
A systematic review to summarize treatment patterns, guidelines, and characteristics of patients with renal cell carcinoma in the Asia-Pacific region	12
Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy	12
What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?	12
Targeting GPRC5D in multiple myeloma	12
From macroscopic clearance to molecular eradication: paradigm shift and future perspectives in the detecting of residual lesions after transurethral resection of bladder tumors	12
Outcomes after the watch-and-wait strategy and local excision treatment for rectal cancer: a meta-analysis	11
Management of breast cancer diagnosed during pregnancy: global perspectives	11
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity	11
PROTACs in action: a novel strategy for pancreatic cancer	11
The trend toward more target therapy in pancreatic ductal adenocarcinoma	11
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review	11
Nivolumab plus ipilimumab in malignant pleural mesothelioma	11
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and	11
CRISPR: a precise genome editing strategy for the treatment of hepatocellular carcinoma	11
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives	11
Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors	11
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer	11
Efficacy and safety of anti-angiogenesis agents combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: a meta-analysis of randomized controlled trials	10
Genetic investigation in patients with histological variants of bladder cancer: clinical implications	10
Upper and lower limb cryotherapy as a preventive strategy for taxane-induced peripheral neuropathy in breast cancer patients: a systematic review and meta-analysis	10
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC)	10
Anticancer properties of histone deacetylase inhibitors – what is their potential?	10
Emerging treatment options for prostate cancer	10
Interventions to reduce the risk of side-effects of cancer treatments in childhood	10
A neurocentric model of survivorship: rethinking success when the mind and nerves don’t recover	10
Novel breakthroughs in advanced prostate cancer management	10
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?	10
What’s to come in PSMA therapies and diagnostics: A summary of clinical trials involving PSMA radioligand-based therapeutic and/or diagnostic approaches with active recruitment	10
Benign and malignant cardiac masses: long-term outcomes after surgical resection	10
Drugging the DNA damage response in the clinic: going beyond PARP	10
Differentiated thyroid cancer and positron emission computed tomography: when, how and why?	10
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond	10
Image-guided radiotherapy (IGRT) in Lombardy, Italy: a survey by the Lombardy section of the Italian Association of Radiotherapy and Clinical Oncology (AIRO-Lombardy)	9
Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors	9
Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing	9
Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma	9
JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway	9

The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol	9
Oligometastases in head and neck squamous cell carcinoma patients	9
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials	9
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablation	9
CRISPR–mRNA synergy: toward adaptive cancer immunotherapy	9
Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials	8
Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis	8
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers	8
ESMO 2025 and new therapies in breast cancer: does society always benefit?	8
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer	8
Venetoclax and beyond: New Horizons in CLL and AML therapy	8
Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies	8
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?	8
Compression therapy for the prevention of taxane-induced peripheral neuropathy in breast cancer: a systematic review and meta-analysis	8
Fixed-duration BTKi-venetoclax combinations in CLL: optimizing patient-centered care	7
Immune checkpoint inhibition in early-stage triple-negative breast cancer	7
Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review	7
Epigenetic targeting in oral squamous cell carcinoma: mechanisms, therapies, and translational potential	7
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?	7
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?	7
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?	7
An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)	7
The association between HALP score and survival in patients treated with immune checkpoint inhibitors	7
Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature	7
Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment	7
The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma	7
Ablative margins in percutaneous thermal ablation of hepatic tumors: a systematic review	6
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy	6
Medullary thyroid carcinoma: a narrative historical review	6
Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia	6
Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study	6
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis	6
Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer	6
Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis	6
Mucosa-associated lymphoid tissue lymphoma in thymus: a SEER analysis	6
Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic	6
Circadian rhythm-based cancer therapy in randomised clinical trials	6
Contemporary management of advanced gastric and gastroesophageal adenocarcinomas	6
From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancer	6
Management of oligometastatic and oligoprogressive renal cell carcinoma: an updated review	6
Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review	6
Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis	6
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC	6
Reevaluating the promise: is primary tumor surgery really the key to survival or just a misinterpretation in de novo stage IV breast cancer?	6
Future directions for antibody-drug conjugates in urothelial cancer	6
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer	6
The relationship between statin use and breast cancer risk: NHANES 2003–2016 and Mendelian randomization study	6
The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations	6
Overcoming common emerging barriers to effective neoadjuvant immunotherapies	6
The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis	6
Pathology, molecular biology, medical oncology, and radiotherapy implications of lung neuroendocrine neoplasm classification: a multidisciplinary perspective	6
Is the ketogenic diet still controversial in cancer treatment?	6
Efficacy of doxorubicin and lipiodol therapy by trans-arterial chemoembolization in hepatocellular carcinoma Egyptian patients and relation to genetic polymorphisms	6
FLT3 -mutated AML: immune evasion through exosome-mediated mechanisms and innovative combination therapies targeting immune escape	5
Current and emerging treatment options for BRAFV600-mutant melanoma	5
Primary site and treatment impact in unresectable metastatic colorectal cancer	5
The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer	5
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma	5
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors	5
Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis	5
Desmoplastic small round cell tumor: from state of the art to future clinical prospects	5
Recent advances in photodynamic therapy combined with chemotherapy for cervical cancer: a systematic review	5
Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis	5
Toward clinical translation of AI-Led drug discovery in endometrial cancer	5
The role of planetary health in urologic oncology	5
Bevacizumab-containing treatment for relapsed or refractory Wilms tumor	5
Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas	5
Safety of PD-L1 inhibitors versus PD-1 inhibitors in the treatment of lung cancer: a systematic review and network meta-analysis	5
Relugolix in the management of prostate cancer	5
How can we refine the prognostic stratification of triple-negative breast cancer?	5
Predicting neoadjuvant chemoradiotherapy response with functional imaging and liquid biomarkers in locally advanced rectal cancer	5
Prognostic value of circulating long non-coding RNAs in colorectal cancer patients: a meta-analysis	5
Therapeutic patterns and outcomes in older patients (aged≥65 years) with stage III-IVB inoperable oral cavity squamous cell carcinoma (OCSCC): an investigational study from the SEER database	5
Harnessing the power of artificial intelligence for clinical trials in cancer	5
How can we address the challenge of distant metastases in HNSCC prognosis?	5
An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors	5
Analysis of the efficacy of paclitaxel combined with bevacizumab intraperitoneal instillation in common gastrointestinal malignant peritoneal effusions and screening of prognostic indicators	5
Cancer immunotherapy efficacy and machine learning	5
Diagnostic performance of urine and blood microRNAs for bladder cancer: a meta-analysis	5
PSMA PET or conventional imaging in metastatic hormone-sensitive prostate cancer?	5

Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters	5
Recent advances in the management of intrahepatic cholangiocarcinoma: the role of actionable mutations and targeted therapies	5
Prognostic value of the body composition parameters in patients with colorectal liver metastases undergoing intra-arterial treatment	5
Integrating PET/CT into breast cancer care: a review of recent developments	5
Addressing the need for more therapeutic options in neuroendocrine prostate cancer	5
Clarifications and comments on “infrared radiation for cancer hyperthermia: the light to brighten up oncology”	5
The multidisciplinary management of locally advanced rectal cancer	5
The role of immune checkpoint inhibitors in the management of NMIBC: a scoping review of current status and future direction	5
Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer	5
Clear cell sarcoma: state-of-the art and perspectives	5
Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs	5
RASGEF1C affects aerobic glycolysis and facilitates lung cancer progression through the PLK1 signaling pathway	5